• Ceftolozane Sulfate: Optimizing PK/PD and Bactericidal Assay

  2026-08-01

  Ceftolozane sulfate empowers researchers to model and overcome multidrug-resistant Pseudomonas aeruginosa with robust activity and protocol flexibility. This guide translates new reference findings and hands-on troubleshooting into actionable workflows for both in vitro and in vivo antibacterial research.

• H3K18 Lactylation Drives NOD2-Mediated Pyroptosis in Astrocy

  2026-07-31

  Li et al. reveal that H3K18 lactylation in astrocytes, triggered by bilirubin, enhances NOD2 expression and promotes pyroptosis, deepening our understanding of neuroinflammation in bilirubin encephalopathy. These findings highlight a novel epigenetic mechanism with therapeutic implications for neonatal brain injury.

• Tubastatin A Mitigates Post-Resuscitation Cardiac Damage via

  2026-07-31

  A recent porcine study demonstrates that Tubastatin A, a selective HDAC6 inhibitor, significantly reduces myocardial injury following cardiac arrest and resuscitation by suppressing pyroptosis and necroptosis pathways. These mechanistic findings expand the therapeutic relevance of HDAC6 inhibition beyond oncology into acute cardiac injury models.

• Safe DNA Gel Stain: Raising Standards in Nucleic Acid Detect

  2026-07-30

  This thought-leadership article explores how Safe DNA Gel Stain, a less mutagenic alternative to ethidium bromide, transforms nucleic acid detection for translational research. Integrating mechanistic insights, protocol parameters, and strategic foresight, it offers evidence-backed guidance for safer, more precise molecular biology workflows—while bridging experimental innovation with clinical relevance.

• CX-4945 (Silmitasertib): Empowering CK2 Inhibition Workflows

  2026-07-30

  CX-4945 (Silmitasertib) delivers reliable, selective CK2 inhibition for dissecting oncogenic signaling, apoptosis, and cell cycle control—enabling translational research from bench to preclinical models. This guide demystifies advanced protocol setup, troubleshooting, and key innovations, including actionable insights from recent lung cancer stemness research.

• Temafloxacin (SKU BA1108): Reliable Antibacterial Agent Work

  2026-07-29

  This article guides biomedical researchers and lab technicians through key challenges in antibacterial assay development, focusing on reproducibility, sensitivity, and data interpretation. Leveraging published data and real-world scenarios, it demonstrates how Temafloxacin (SKU BA1108) from APExBIO offers validated solutions for Gram-positive and Gram-negative infection models, respiratory pathogens, and intracellular bactericidal assays.

• Fulvestrant (ICI 182,780): Optimizing ERα Antagonism in Brea

  2026-07-29

  Fulvestrant (ICI 182,780) stands out as a versatile tool for dissecting estrogen receptor signaling, post-translational protein regulation, and chemotherapy sensitization in advanced breast cancer models. This guide delivers actionable protocols, troubleshooting strategies, and evidence-based workflow tips to maximize experimental rigor and reproducibility.

• Sulfo-Cy5 Carboxylic Acid: Precision Fluorescence in Nanovac

  2026-07-28

  Explore how Sulfo-Cy5 carboxylic acid advances fluorescence imaging in life sciences, enabling nuanced assay development for nanovaccine research. This article offers unique technical and methodological insights beyond standard applications.

• Promethazine HCl in Research: Beyond Host-Directed Antibacte

  2026-07-28

  Discover how promethazine hydrochloride enables advanced research into histamine signaling, immune cell metabolism, and host-pathogen interactions. This article explores new experimental frontiers, detailed protocols, and practical insights for scientists using Promethazine HCl.

• Prosapogenin A Induces Pyroptosis in ATC via Lysosomal Acidi

  2026-07-27

  This study uncovers a novel mechanism by which Prosapogenin A (PA) triggers GSDME-dependent pyroptosis in anaplastic thyroid cancer (ATC) cells through vacuolar ATPase-driven lysosomal over-acidification. The findings highlight lysosomal vulnerability as a therapeutic target and provide a mechanistic foundation for developing new interventions in aggressive thyroid cancers.

• Stiripentol as an LDH Inhibitor: Optimizing Metabolic Assays

  2026-07-27

  Stiripentol provides unique noncompetitive LDH inhibition for precise control of lactate metabolism in epilepsy and immunometabolic research. This guide details experimental workflows and troubleshooting strategies, translating recent mechanistic insights into actionable protocols for scientists.

• Palbociclib (PD0332991) Isethionate: Assay Design and Biomar

  2026-07-26

  Discover how Palbociclib (PD0332991) transforms cell cycle research and cancer assay design. This article uniquely bridges targeted CDK4/6 inhibition with biomarker-guided strategies for translational cancer studies.

• Transmission Dynamics of Carbapenemase Genes in CREC in Guan

  2026-07-25

  This study provides a detailed genomic and epidemiological characterization of carbapenemase-encoding gene (CEG) distribution and transmission in carbapenem-resistant Enterobacter cloacae (CREC) isolates from eight teaching hospitals in Guangdong, China. The findings reveal high prevalence and efficient transfer of blaNDM-1 and other CEGs, underscoring urgent challenges for antimicrobial resistance surveillance and infection control.

• mRNA-LNP Programming of CAR Macrophages for Peritoneal Tumor

  2026-07-24

  This study introduces a macrophage-targeted mRNA lipid nanoparticle platform to program tailored CAR macrophages directly within the peritoneal cavity. The findings reveal that specific CAR intracellular domain configurations enhance anti-tumor immunity and synergize with checkpoint inhibitors, providing a promising strategy for hard-to-treat peritoneal metastases.

• Cefodizime: Antibacterial Activity, Pharmacokinetics, and Th

  2026-07-24

  The reference review systematically details cefodizime’s broad-spectrum antibacterial activity, pharmacokinetic profile, and therapeutic efficacy in respiratory and urinary tract infections. Notably, it highlights cefodizime’s potential immunomodulatory effects and favorable tolerability, positioning it as a clinically relevant third-generation cephalosporin for standard and special patient populations.

446 records 9/30 page Previous Next First page 上5页 678910 下5页 Last page